Akebia Therapeutics to Present Late-Breaking VOICE Trial Data at ASN Kidney Week 2026
Event summary
- Akebia Therapeutics will present late-breaking data from the VOICE trial at ASN Kidney Week 2026, evaluating vadadustat vs. erythropoiesis-stimulating agents (ESAs) in hemodialysis patients.
- The company will showcase multiple posters on its rare kidney disease pipeline, including praliciguat for FSGS and ebribafusp alfa for complement-mediated kidney diseases.
- Posters will also highlight clinical and economic outcomes associated with Vafseo® (vadadustat).
- ASN Kidney Week 2026 takes place in Denver, CO from October 21-25, 2026.
The big picture
Akebia Therapeutics is positioning itself as a key player in the rare kidney disease space, with a focus on innovative treatments for conditions like FSGS and complement-mediated kidney diseases. The upcoming presentations at ASN Kidney Week 2026 are critical for validating the company's pipeline and potentially expanding the market for its lead product, Vafseo® (vadadustat). The strategic focus on cost analysis and clinical outcomes underscores the competitive landscape in the treatment of anemia in chronic kidney disease.
What we're watching
- Clinical Efficacy
- How the VOICE trial results will impact the adoption of vadadustat in hemodialysis patients.
- Pipeline Progress
- Whether the preclinical and Phase 2 data for praliciguat and ebribafusp alfa will accelerate their development timelines.
- Market Positioning
- The pace at which Akebia can differentiate Vafseo® from existing ESAs based on cost and clinical outcomes.